Neurology

In a groundbreaking new study, researchers have identified a molecular pathway for stimulating the regeneration of new myelinating cells, and repairing the damage of debilitating neurological diseases.

Study finds that several multiple sclerosis drug candidates inhibit the same enzyme to stimulate myelin regeneration.

Blocking the protein receptor, muscarinic type 3, may be effective in promoting remyelination in patients with multiple sclerosis.

Using targeted therapies in patients with gliobastoma who have the mutation may reduce tumor growth and improve survival outcomes.

Mapping iron concentration in certain regions of the brain may help predict multiple sclerosis progression risk.

New research has associated certain health problems with later diagnosis of multiple sclerosis.

The investigational treatment could benefit patients with amyotrophic lateral sclerosis whose disease is caused by mutations in the SOD1 gene.

Supplementation of the protein in the nerve cells prevented nerve degeneration, muscle atrophy, and paralysis in an amyloid lateral sclerosis mouse model.

Most individuals with multiple sclerosis experience pain as a symptom of the disease.

Researchers aim to determine whether an annual brain volume loss rate of less than 0.4% is a valid marker to assess treatment response.

Cognitive impairment is present in up to 70% of patients with multiple sclerosis, but can be difficult to completely evaluate in routine clinical practice.

Research to explore whether intermittent fasting can improve symptoms in patients with relapsing-remitting multiple sclerosis.

Multiple sclerosis risk increased significantly in individuals with occupational exposure to organic solvents.

IncobotulinumtoxinA is the first and only neurotoxin approved for this indication in the United States.

Two recent studies examined the different effects and aspects of progressive multiple sclerosis.

Two recent clinical trials evaluated the efficacy of the drug ozanimod, an investigational drug for the treatment of relapsing multiple sclerosis.

A look at last week's top stories in the world of pharmacy.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The findings highlight the role of Epstein-Barr virus (EBV) infection in multiple sclerosis pathogenesis and support therapies targeting EBV-infected immune cells.

Top news of the week from Specialty Pharmacy Times.

Researchers identified an epigenetic mechanism connected to a known genetic risk factor for multiple sclerosis.

Phase 3 data show that ocrelizumab (Ocrevus) may delay the progression of disability, such as the need for a wheelchair, in patients with primary progressive multiple sclerosis (PPMS).

Researchers investigated whether high body mass index is a risk factor not only for a greater risk of multiple sclerosis, but also for advancing to the secondary progressive stage of the disease.

Top news of the day from across the health care landscape

Researchers identified a primary mechanism of inflammatory demyelination in the central nervous system during multiple sclerosis, which may lead to new therapeutic approaches.